Jon S. Zawistowski, Ph.D.
Affiliations: | 2005 | Duke University, Durham, NC |
Area:
Genetics, Molecular BiologyGoogle:
"Jon Zawistowski"Parents
Sign in to add mentor| Douglas Marchuk | grad student | 2005 | Duke | |
| (Molecular analysis of the cerebral cavernous malformations gene products.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Goulet DR, Foster JP, Zawistowski JS, et al. (2020) Discrete Adaptive Responses to MEK Inhibitor in Subpopulations of Triple-Negative Breast Cancer. Molecular Cancer Research : McR |
| Bevill SM, Olivares-Quintero JF, Sciaky N, et al. (2019) GSK2801, a BAZ2/BRD9 bromodomain inhibitor, synergizes with BET inhibitors to induce apoptosis in triple-negative breast cancer. Molecular Cancer Research : McR |
| Allaway R, Angus SP, et al. (2018) Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. Plos One. 13: e0197350 |
| Collins KAL, Stuhlmiller TJ, Zawistowski JS, et al. (2018) Proteomic analysis defines kinase taxonomies specific for subtypes of breast cancer. Oncotarget. 9: 15480-15497 |
| Zawistowski J, Bevill S, Johnson GL. (2018) Abstract IA23: Enhancer remodeling in response to MEK inhibition in TNBC Molecular Cancer Research. 16 |
| Bevill SM, Sciaky N, Golitz BT, et al. (2018) Abstract B34: Novel synergistic combination therapies with BET bromodomain inhibitors in triple-negative breast cancer Molecular Cancer Research. 16 |
| Bevill SM, Zawistowski JS, Johnson GL. (2017) Enhancer remodeling regulates epigenetic adaptation and resistance to MEK1/2 inhibition in triple-negative breast cancer. Molecular & Cellular Oncology. 4: e1300622 |
| Stuhlmiller TJ, Zawistowski JS, Chen X, et al. (2017) Kinome and Transcriptome Profiling Reveal Broad and Distinct Activities of Erlotinib, Sunitinib, and Sorafenib in the Mouse Heart and Suggest Cardiotoxicity From Combined Signal Transducer and Activator of Transcription and Epidermal Growth Factor Receptor Inhibition. Journal of the American Heart Association. 6 |
| Angus SP, Zawistowski JS, Johnson GL. (2017) Epigenetic Mechanisms Regulating Adaptive Responses to Targeted Kinase Inhibitors in Cancer. Annual Review of Pharmacology and Toxicology |
| Mobley RJ, Raghu D, Duke LD, et al. (2017) MAP3K4 Controls the Chromatin Modifier HDAC6 during Trophoblast Stem Cell Epithelial-to-Mesenchymal Transition. Cell Reports. 18: 2387-2400 |